Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

FDA Approves NovoLog(R) Labeling Update Increasing The Time Patients Can Use And Store NovoLog(R) In Their Pumps From Two Days To Six Days
Diabetes patients taking NovoLog® (insulin aspart [rDNA origin] injection) can now use the insulin in their pump for up to six days following the U.S. Food and Drug Administration (FDA) approval of a labeling change, diabetes care company Novo Nordisk announced today.[i] The previous label allowed for NovoLog® to be stored in the pump reservoir for two days. This makes NovoLog® the first and only rapid-acting insulin with this extended in-use time.

Grant From American Heart Association For Cardiac Myogenesis Research Center At UT Southwestern
UT Southwestern Medical Center researchers Drs. Jay Schneider, Joseph Hill and Eric Olson have been awarded a $2 million grant from the American Heart Association to study the development and mechanisms of generating new cardiac muscle cells.
News of the day
Sunbeds And UV Classed As Definitely Cancer-Causing
Global health experts have moved use of sunbeds and exposure to ultraviolet radiation (including sun exposure) to the highest risk category for causing cancer: they
Oncology

Primary Insomnia Linked To A Neurochemical Abnormality

A research abstract presented on June 9, at SLEEP 2009, the 23rd Annual Meeting of the Associated Professional Sleep Societies, is the first demonstration of a specific neurochemical abnormality in adults with primary insomnia (PI), providing greater insight to the limited understanding of the condition"s pathology. Results indicate that gamma-aminobutyric acid (GABA), the most common inhibitory transmitter in the brain, is reduced by nearly 30 percent in individuals who suffer from primary insomnia for more than six months. These findings suggest that primary insomnia is a manifestation of a neurobiological state of hyperarousal, which is present during both waking and sleep at physiological and cognitive levels. According to principal investigator Dr. John Winkelman of Brigham and Women"s Hospital, at Harvard Medical School in Boston, Mass., the recognition that primary insomnia is associated with a specific neurochemical deficiency helps validate the often misunderstood complaint of insomnia. "Recognition that insomnia has manifestations in the brain may increase the legitimacy of those who have insomnia and report substantial daytime consequences," he said. "Insomnia is not just a phenomenon observed at night, but has daytime consequences for energy, concentration and mood." The study included 16 non-medicated individuals (eight of whom were women) with PI and 16 individuals (seven women) who were deemed normal sleepers. Global brain GABA levels were measured in both groups. PI was established through clinical interviews, sleep diary, actigraphy use and polysomnograpy. Winkelman published similar results in the Nov. 1, 2008, issue of the journal SLEEP. Abstract Title: Reduced brain GABA in primary insomnia: preliminary data from 4T proton magnetic resonance spectroscopy (1H-MRS) Presentation Date: Tuesday, June 9 Category: Sleep Disorders - Insomnia Abstract ID: 0768 Kelly Wagner American Academy of Sleep Medicine


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009